Skip to main content

NOA, a disruptive portable device to monitor asthma

Periodic Reporting for period 1 - NOA (NOA, a disruptive portable device to monitor asthma)

Reporting period: 2017-06-01 to 2017-11-30

The NOA project by Eversens S.L. was approved within the call for SME Instrument H2020, Topic SMEInst-01-2016-2017: Open Disruptive Innovation Scheme, Call 2017-02-15.

Thanks to the Phase 1 project granted, Eversens has been able to improve its Feasibility Study.

The Global Burden of Diseases Study indicates that as many as 334 million people in the world have asthma. In Europe, about 30 million children and adults under 45 years old have asthma.

There is no cure for asthma, it is a chronic disease. Asthma can have a very negative impact on the quality of life of those people who suffer from it. However, it can be diagnosed and effectively controlled at an early stage.

We have developed the EverNoa device (called previously NOA), which monitors asthma in a simple, painless, non-invasive and precise way, with accurate and immediate results. The EverNoa is useful for both preventive and post-treatment monitoring.

The basis of the EverNoa device is its ability to measure the Fraction of Exhaled Nitric Oxide (FeNO) of human breath, which is a marker that indicates the existence and extent of inflammation into airways caused by asthma.

The overall objective of the Project is to confirm the business strategy, business model, intellectual property and marketing strategies of the company Eversens, S.L. to enter into the e-health and medical devices sectors, through the EverNoa.

To do so, we have improved our business plan to allows the international business expansion of our company.

The Project has been developed as planned, in terms of deadlines, budgets, actions, and results obtained.
The first activity of the project has enabled us to research the processes followed for purchasing devices for medical centres. We also have identified the public entities that make decisions about the inclusion of medical treatments and devices onto the reimbursement systems of each country.

After that, we have compiled a list of more than 300 companies that distribute across different European countries products complementary to our EverNoa and we have made advancements in testing agreements with two of them. We have also developed a model of agreement for distributors.

On the other hand, we have also found several reference hospitals in the treatment of asthma in Europe, and design a model according to these, to provide them with an EverNoa device.

According to our IP strategy, we have managed to register a PCT, a European trademark and a European design. In addition, we have laid the foundations to continue protecting new developments. The IP protection strategy has become a strength of Eversens for commercial deployment at an international level.

Finally, the business model has been rethought employing the Canvas methodology and we have improved our business plan, including economic and financial projections for the next five years.

We should note that the three business coaching sessions were very profitable. The coaching has contributed to understanding of the specific key points to access the medical device market in Europe. It has also contributed to identifying the strengths and weaknesses of the project and to prioritizing the company's objectives and reinforcing the need to promote the market access department of the company.
We want to bring to the European market an innovative product that helps to improve the control and treatment of disease, asthma, which affects the health of more than 10% of Europeans under 45 years old.

The EverNoa solution will have a significant impact on the improvement of life quality in people in Europe, contributing to improve the diagnosis, treatment and monitoring of asthma, which is one of the “major and chronic diseases” pointed to by the European Commission.

The EverNoa will contribute to an early diagnosis of the disease in these people, with the consequent improvement in their quality of life and generating significant savings in European health systems. The EverNoa also helps to improve the control of the disease, releasing patients from self-diagnostic decisions and removing the waiting time in seeking medical advice.

Promoters expect to demonstrate that Eversens SL will soon be an internationally recognized company within the field of non-invasive clinical diagnosis systems through the detection of exhaled biomarkers.

Eversens SL will have generated a significant number of jobs, as well as important economic surpluses.
EverNoa Logo